Patents by Inventor Stuart William Hicks

Stuart William Hicks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230203202
    Abstract: Multispecific binding proteins that bind NKG2D receptor, CD16, and 5T4 are described, as well as pharmaceutical compositions, formulations, and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer.
    Type: Application
    Filed: December 6, 2022
    Publication date: June 29, 2023
    Inventors: Mitchell Bigelow, Mark DeRose, Jinyan Du, Robin Friedman, Pyae P. Hein, Stuart William Hicks, Zong Sean Juo, Xinbi Li, Christopher Ryan Morgan
  • Publication number: 20210388102
    Abstract: The present invention is directed to immunoconjugates comprising an antibody or fragment thereof capable of specifically binding to “Disintegrin and Metalloproteinase Domain-containing Protein 9” (“ADAM9”) conjugated to at least one pharmacological agent. The invention particularly concerns such immunoconjugates that are cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such immunoconjugates that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such immunoconjugate to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such immunoconjugates, and to methods involving the use of any of such immunoconjugates in the treatment of cancer and other diseases and conditions.
    Type: Application
    Filed: December 21, 2017
    Publication date: December 16, 2021
    Inventors: Stuart William Hicks, Nicholas C. Yoder, Bhaswati Barat, Ezio Bonvini, Gundo Diedrich, Leslie S. Johnson, Deryk Loo, Juniper A. Scribner
  • Publication number: 20210275685
    Abstract: The present invention is directed to immunoconjugates comprising an antibody or fragment thereof capable of specifically binding to “Disintegrin and Metalloproteinase Domain- containing Protein 9” (“ADAM9”) conjugated to at least one maytansinoid compound. The invention particularly concerns such immunoconjugates that are cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such immunoconjugates that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such immunoconjugate to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such immunoconjugates, and to methods involving the use of any of such immunoconjugates in the treatment of cancer and other diseases and conditions.
    Type: Application
    Filed: June 25, 2019
    Publication date: September 9, 2021
    Inventors: Stuart William Hicks, Nicholas C. Yoder, Bhaswati Barat, Ezio Bonvini, Gundo Diedrich, Leslie S. Johnson, Deryk Loo, Juniper A. Scribner
  • Publication number: 20180230218
    Abstract: MET is a receptor tyrosine kinase found on the surface of tumor cells. The present invention includes anti-MET antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
    Type: Application
    Filed: January 3, 2018
    Publication date: August 16, 2018
    Inventors: Thomas Chittenden, Jutta Deckert, Stuart William Hicks, Katharine C. Lai, Peter U. Park, Lingyun Rui, Daniel J. Tavares, Neeraj Kohli